Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group.
Olivier HermineXavier MarietteRaphael PorcherMatthieu Resche-RigonPierre-Louis TharauxPhilippe Ravaudnull nullPublished in: The European respiratory journal (2022)
In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.